Some companies are marketing a new test—the nipple aspirate test—as the latest and greatest tool in early breast cancer screening. But FDA warns that the nipple aspirate test is no substitute for a mammogram.
Related Articles Read More >
Catching up with Dr. Tom Oxley as Synchron builds toward a pivotal trial for FDA approval of its Stentrode BCI
Sept. 25-26: Live interviews and audience Q&As with minimally invasive engineers from J&J, Abbott and more
As cardiovascular deaths soar for women, Medtronic’s Nina Goodheart and the medtech industry are responding
